tradingkey.logo

Recludix Pharma Announces Equity Financing To Advance Clinical Development Of Novel Sh2 Domain Inhibitors

ReutersJan 12, 2026 1:11 PM

- Eli Lilly and Co LLY.N:

  • RECLUDIX PHARMA : ANNOUNCES EQUITY FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF NOVEL SH2 DOMAIN INHIBITORS

  • RECLUDIX PHARMA : FINANCING LED BY INSTITUTIONAL INVESTORS, WITH PARTICIPATION FROM NEW INVESTOR ELI LILLY AND COMPANY

  • RECLUDIX PHARMA : TOTAL OF $123 MILLION IN EQUITY FINANCING RECEIVED FROM INSTITUTIONAL AND STRATEGIC INVESTORS TO DATE

  • RECLUDIX PHARMA : ANNOUNCES COLLABORATION WITH LILLY TO UTILIZE LILLY TUNELAB TO ACCELERATE DEVELOPMENT OF RECLUDIX’S DISCOVERY PIPELINE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI